Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 known ✓ | P49810 | 1/20 | 0.50 |
| ▸ | APH1B known ✓ | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN known ✓ | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A known ✓ | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 1/20 | 0.50 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16178922 | 1.00 | GRIN1 (0.54) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL144720 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL29875956 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL28175592 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL19313988 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL144721 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL350132 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| SCHEMBL20677083 | 0.98 | GRIN1 (0.55) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| Charcoal, Activated SCHEMBL30693761 | 0.97 | GRIN1 (0.54) | GRIN1GRIN2BCYP19A1GPBAR1LMNA | |
| Water SCHEMBL28180475 | 0.97 | GRIN1 (0.54) | GRIN1GRIN2BCYP19A1GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719030-B1 | 19-NOR NEUROACTIVE STEROIDS FOR INDUCING SEDATION | SAGE THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240076310-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | Sage Therpeutics, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4144746-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11261211-B2 | 19-NOR neuroactive steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3909966-A1 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3498725-B1 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR USE IN THERAPY | SAGE THERAPEUTICS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210139531-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210061850-A1 | NEUROACTIVE STERIODS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2014169832-A9 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2014169833-A9 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| EP-2986624-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986623-A1 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2016-02-24 | — | — | EP | disclosed |
| CN-105339381-A | 19-nor C3, 3-disubstituted C21-N-pyrazolylsterols and methods of use thereof | SAGE THERAPEUTICS INC | 2016-02-17 | — | — | CN | disclosed |
| CN-105246909-A | 19-nor steroids that stimulate neural activity and methods of use thereof | SAGE THERAPEUTICS INC | 2016-01-13 | — | — | CN | disclosed |
| WO-2015180679-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2014169833-A1 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014169832-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014169836-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076310-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CNR1, NR3C2, CNR2 | PSEN1 343/4885PSEN2 453/4885APH1B 291/4885 |
| US-20210061850-A1 | NEUROACTIVE STERIODS, COMPOSITIONS, AND USES THEREOF | HSD3B1, HTR3B, HSD3B2 | PSEN1 655/4885PSEN2 787/4885APH1B 555/4885 |
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, HSD3B2 | PSEN1 216/4885PSEN2 252/4885APH1B 189/4885 |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | NR3C2, NR3C1, CYP11B1 | PSEN1 249/4885PSEN2 386/4885APH1B 286/4885 |
| US-20210139531-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | PSEN1 216/4885PSEN2 252/4885APH1B 189/4885 |
| US-11261211-B2 | 19-NOR neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, NR3C1 | PSEN1 190/4885PSEN2 275/4885APH1B 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.